Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo, Japan;
Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo, Japan.
In Vivo. 2022 Mar-Apr;36(2):865-873. doi: 10.21873/invivo.12775.
BACKGROUND/AIM: We aimed to investigate the association between The Geriatric Nutritional Risk Index (GNRI) and the tolerability of lenvatinib in patients with hepatocellular carcinoma (HCC).
We retrospectively evaluated 61 HCC patients treated with lenvatinib and compared those with low GNRI (≤98, n=26) to those with high GNRI (>98, n=35).
The discontinuation of lenvatinib due to adverse events was more frequent in the low GNRI group (46.2%) than in the high GNRI group (17.1%) (p=0.014). Multivariate analysis revealed that low GNRI (p=0.014), hypothyroidism (model 1 p=0.021, model 2 p=0.013), and advanced age (p=0.026) were independently associated with the discontinuation of lenvatinib. The progression-free survival in the low GNRI group was significantly shorter than that in the high GNRI group (p=0.047).
The GNRI might be independently associated with the tolerability of lenvatinib in patients with HCC.
背景/目的：我们旨在研究老年营养风险指数（GNRI）与肝癌（HCC）患者仑伐替尼耐受性之间的关系。
我们回顾性评估了 61 例接受仑伐替尼治疗的 HCC 患者，并将 GNRI 低（≤98，n=26）与 GNRI 高（>98，n=35）的患者进行比较。
低 GNRI 组（46.2%）仑伐替尼因不良事件停药的频率高于高 GNRI 组（17.1%）（p=0.014）。多变量分析显示，低 GNRI（p=0.014）、甲状腺功能减退症（模型 1 p=0.021，模型 2 p=0.013）和高龄（p=0.026）与仑伐替尼停药独立相关。低 GNRI 组的无进展生存期明显短于高 GNRI 组（p=0.047）。
GNRI 可能与 HCC 患者仑伐替尼的耐受性独立相关。
